<DOC>
	<DOCNO>NCT00698269</DOCNO>
	<brief_summary>This study conduct Asia . The aim observational study evaluate safety efficacy modern insulin switch anti-diabetic treatment normal clinical condition Gulf country .</brief_summary>
	<brief_title>An Observational Study Efficacy Safety Modern Insulin Diabetes Patients Switched From Anti-diabetic Treatment</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Type 1 type 2 diabetes Treatment diabetes treatment NovoMix® 30 , Levemir® and/or NovoRapid® Selection discretion individual physician Current treatment Levemir® , NovoMix® 30 and/or NovoRapid® Previous enrol study Hypersensitivity Levemir® , NovoMix® 30 and/or NovoRapid® excipients Women pregnant , breast feeding intention become pregnant within next 6 month</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>